Auris Medical Holding AG (EARS) Reaches $0.39 Yearly Low; COINSILIUM GROUP LTD ORD VIRGIN (CINGF) Shorts Increased By 172.19%

December 7, 2017 - By Richard Conner

The stock of Auris Medical Holding AG (NASDAQ:EARS) hit a new 52-week low and has $0.38 target or 3.00% below today’s $0.39 share price. The 5 months bearish chart indicates high risk for the $17.34M company.

The 1-year low was reported on Dec, 7 by Barchart.com. If the $0.38 price target is reached, the company will be worth $520,110 less. The stock decreased 2.23% or $0.0089 during the last trading session, reaching $0.3911. About 160,581 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 79.78% since December 7, 2016 and is downtrending. It has underperformed by 96.48% the S&P500.

COINSILIUM GROUP LTD ORD VIRGIN (OTCMKTS:CINGF) had an increase of 172.19% in short interest. CINGF’s SI was 287,700 shares in December as released by FINRA. Its up 172.19% from 105,700 shares previously. With 268,100 avg volume, 1 days are for COINSILIUM GROUP LTD ORD VIRGIN (OTCMKTS:CINGF)’s short sellers to cover CINGF’s short positions. The stock increased 9.09% or $0.02 during the last trading session, reaching $0.18. About 233,417 shares traded or Infinity% up from the average. Coinsilium Group Limited (OTCMKTS:CINGF) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. Jefferies maintained Auris Medical Holding AG (NASDAQ:EARS) on Tuesday, March 15 with “Buy” rating. The company was initiated on Friday, June 30 by Roth Capital. Needham maintained the shares of EARS in report on Friday, August 19 with “Buy” rating.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company has market cap of $17.34 million. The Company’s product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. It currently has negative earnings. The firm is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123.

Coinsilium Group Limited is a venture capital firm specializing in early stage startup and accelerating seed-stage investment in Fintech sector. The company has market cap of $16.66 million. The firm primarily invests in companies who are pioneering new applications that leverage and commercialize blockchain technologies and financial technology including Bitcoins, Internet of Things, wallets, payment gateways, exchanges, security solutions, applications, and financial services. It currently has negative earnings. It typically invests in Europe, Asia, and US, but may consider investments in other parts.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>